Antihypertensives for combating dementia A perspective on candidate molecular mechanisms and population-based prevention

Translational Psychiatry

Volumn 2, Issue , 2012, Pages

  Valenzuela, M ^a,b,c   Esler, M ^d   Ritchie, K ^e,f   Brodaty, H ^b,c,g  

^a UNIVERSITY OF SYDNEY   (Australia)

^b PRINCE OF WALES HOSPITAL   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d MONASH UNIVERSITY   (Australia)

^e INSERM   (France)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

^g UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Alzheimer's disease; cerebrovascular disease; dementia; hypertension; prevention

Indexed keywords

ALPHA TOCOPHEROL; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INDAPAMIDE; PERINDOPRIL;

ALZHEIMER DISEASE; ANTIHYPERTENSIVE THERAPY; BRAIN FUNCTION; BRAIN HYPOXIA; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; DEMENTIA; DIASTOLIC BLOOD PRESSURE; HUMAN; HYPERTENSION; MOLECULAR MECHANICS; NEUROPROTECTION; PATHOPHYSIOLOGY; POPULATION RESEARCH; PRIMARY PREVENTION; REVIEW; SYSTOLIC BLOOD PRESSURE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIHYPERTENSIVE AGENTS; BRAIN; BRAIN ISCHEMIA; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; CEREBRAL VENTRICLES; DEMENTIA, VASCULAR; DOUBLE-BLIND METHOD; HUMANS; HYPERTENSION; NEUROPROTECTIVE AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; RISK REDUCTION BEHAVIOR; STROKE; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84860307697     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2012.28     Document Type: Review

References (111)

1. Briganti EM, Shaw JE, Chadban SJ, Zimmet PZ, Welborn TA, McNeil JJ et al. Untreated hypertension among Australian adults: The 1999-2000 Australian Diabetes, Obesity and Lifestyle Study (AusDiab). Med J Aust 2003; 179: 135-139. (Pubitemid 37025189)
2. Lloyd-Jones D, Evans J, Levy D. Hypertension in Adults across the age spectrum: Current outcomes and control in the community. JAMA 2005; 294: 466-472. (Pubitemid 41124179)
3. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 2007; 3: 186-191. (Pubitemid 46825511)
4. Keeping Dementia Front of Mind: Incidence and Prevalence 2009-2050. Report by Access Economics Pty Ltd for Alzheimer's Australia, 2009.
5. Daviglus ML, Plassman BL, Pirzada A, Bell CC, Bowen PE, Burke JR et al. Risk Factors and Preventive Interventions for Alzheimer Disease: State of the Science. Arch Neurol 2011; 68: 1185-1190.
6. Peters R, Beckett N, Forette F, Tuomilehto J, Clarke R, Ritchie C et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): A double-blind, placebo controlled trial. Lancet Neurol 2008; 7: 683-689.
7. Feigin V, Ratnasabapathy Y, Anderson C. Does blood pressure lowering treatment prevents dementia or cognitive decline in patients with cardiovascular and cerebrovascular disease? J Neurol Sci 2005; 229-230: 151-155. (Pubitemid 40341579)
8. McGuinness B, Todd S, Passmore P, Bullock R. The effects of blood pressure lowering on development of cognitive impairment and dementia in patients without apparent prior cerebrovascular disease. Cochrane Database Syst Rev 2006; CD004034.
9. Looi JC, Sachdev PS. Differentiation of vascular dementia from AD on neuropsychological tests. Neurology 1999; 53: 670-678. (Pubitemid 29448284)
10. Korczyn AD. Mixed dementia-the most common cause of dementia. Ann N Y Acad Sci 2002; 977: 129-134. (Pubitemid 35418145)
11. Langa KM, Foster NL, Larson EB. Mixed dementia: Emerging concepts and therapeutic implications. JAMA 2004; 292: 2901-2908. (Pubitemid 39628238)
12. Dickson D. Structural Changes in the Aged Brain. In: Timiras P, Bittar E (eds). Advances in Cell Aging and Gerontology. Jai Press: Greenwich, 1997, pp 51-76.
13. Strozyk D, Dickson DW, Lipton RB, Katz M, Derby CA, Lee S et al. Contribution of vascular pathology to the clinical expression of dementia. Neurobiol Aging 2010; 31: 1710-1720.
14. Neuropathology Group Medical Research Council Cognitive Function and Aging Study. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Lancet 2001; 357: 169-175.
15. Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007; 69: 2197-2204. (Pubitemid 350294674)
16. Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol 2009; 66: 200-208.
17. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 1997; 277: 813-817. (Pubitemid 27111317)
18. Victoroff J, Mack WJ, Lyness SA, Chui HC. Multicenter clinicopathological correlation in dementia. Am J Psychiatry 1995; 152: 1476-1484.
19. Lee JH, Kim SH, Kim GH, Seo SW, Park HK, Oh SJ et al. Identification of pure subcortical vascular dementia using 11C-Pittsburgh compound B. Neurology 2011; 77: 18-25.
20. Deschaintre Y, Richard F, Leys D, Pasquier F. Treatment of vascular risk factors is associated with slower decline in Alzheimer disease. Neurology 2009; 73: 674-680.
21. Launer LJ, Hughes T, Yu B, Masaki K, Petrovitch H, Ross GW et al. Lowering midlife levels of systolic blood pressure as a public health strategy to reduce late-life dementia: Perspective from the Honolulu Heart Program/Honolulu Asia Aging Study. Hypertension 2010; 55: 1352-1359.
22. Safar M. Hemodynamic concepts of hypertension: From the Eindkessel model to large artery compliance and wave reflections. In: Birkenhager W, Robertson J, Zanchetti A (eds). Handbook of Hypertension. Hypertension in the Twentieth Century: Concepts and Achievements, vol. 22, Elsevier: Amsterdam, 2004, pp 173-191.
23. Glagov S, Vito R, Giddens DP, Zarins CK. Micro-architecture and composition of artery walls: Relationship to location, diameter and the distribution of mechanical stress. J Hypertens Suppl 1992; 10: S101-S104.
24. Esler M, Lambert G, Jennings G. Regional norepinephrine turnover in human hypertension. Clin Exp Hypertens A 1989; 11(Suppl 1): 75-89. (Pubitemid 19159111)
25. Padfield PL, Brown JJ, Lever AF, Schalekamp MA, Beevers DG, Davies DL et al. Is lowrenin hypertension a stage in the development of essential hypertension or a diagnostic entity? Lancet 1975; 1: 548-550.
26. Manolio TA, Olson J, Longstreth WT. Hypertension and cognitive function: Pathophysiologic effects of hypertension on the brain. Curr Hypertens Rep 2003; 5: 255-261. (Pubitemid 38914969)
27. Mulvany MJ. Small artery remodeling in hypertension. Curr Hypertens Rep 2002; 4: 49-55.
28. Semplicini A, Maresca A, Sartori M, Calo L, Pessina AC. Hypertension and cerebrovascular diseases: A specific role of vascular protection for the prevention of dementia. J Cardiovasc Pharmacol 2001; 38(Suppl 2): S79-S82. (Pubitemid 34020563)
29. Dufouil C, de Kersaint-Gilly A, Besancon V, Levy C, Auffray E, Brunnereau L et al. Longitudinal study of blood pressure and white matter hyperintensities: The EVA MRI Cohort. Neurology 2001; 56: 921-926. (Pubitemid 32290809)
30. Longstreth Jr WT, Manolio TA, Arnold A, Burke GL, Bryan N, Jungreis CA et al. Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people. The Cardiovascular Health Study. Stroke 1996; 27: 1274-1282. (Pubitemid 26286152)
31. Pantoni L, Garcia JH. The significance of cerebral white matter abnormalities 100 years after Binswanger's report. A review. Stroke 1995; 26: 1293-1301.
32. Fernando MS, Simpson JE, Matthews F, Brayne C, Lewis CE, Barber R et al. White matter lesions in an unselected cohort of the elderly: Molecular pathology suggests origin from chronic hypoperfusion injury. Stroke 2006; 37: 1391-1398. (Pubitemid 44305715)
33. Englund E. Neuropathology of white matter lesions in vascular cognitive impairment. Cerebrovasc Dis 2002; 13(Suppl 2): 11-15. (Pubitemid 34233903)
34. de Groot JC, de Leeuw FE, Oudkerk M, van Gijn J, Hofman A, Jolles J et al. Cerebral white matter lesions and cognitive function: The Rotterdam Scan Study. Ann Neurol 2000; 47: 145-151. (Pubitemid 30078560)
35. Au R, Massaro JM, Wolf PA, Young ME, Beiser A, Seshadri S et al. Association of white matter hyperintensity volume with decreased cognitive functioning: The Framingham Heart Study. Arch Neurol 2006; 63: 246-250. (Pubitemid 43261736)
36. Stewart R, Dufouil C, Godin O, Ritchie K, Maillard P, Delcroix N et al. Neuroimaging correlates of subjective memory deficits in a community population. Neurology 2008; 70: 1601-1607. (Pubitemid 351620315)
37. Dufouil C, Godin O, Chalmers J, Coskun O, MacMahon S, Tzourio-Mazoyer N et al. Severe cerebral white matter hyperintensities predict severe cognitive decline in patients with cerebrovascular disease history. Stroke 2009; 40: 2219-2221.
38. van Straaten EC, Harvey D, Scheltens P, Barkhof F, Petersen RC, Thal LJ et al. Periventricular white matter hyperintensities increase the likelihood of progression from amnestic mild cognitive impairment to dementia. J Neurol 2008; 255: 1302-1308.
39. Wong TY, Klein R, Sharrett AR, Nieto FJ, Boland LL, Couper DJ et al. Retinal microvascular abnormalities and cognitive impairment in middle-aged persons: The Atherosclerosis Risk in Communities Study. Stroke 2002; 33: 1487-1492. (Pubitemid 34619944)
40. Kato H, Izumiyama M, Izumiyama K, Takahashi A, Itoyama Y. Silent cerebral microbleeds on T2*-weighted MRI: Correlation with stroke subtype, stroke recurrence, and leukoaraiosis. Stroke 2002; 33: 1536-1540. (Pubitemid 34619953)
41. Dai W, Lopez OL, Carmichael OT, Becker JT, Kuller LH, Gach HM. Abnormal regional cerebral blood flow in cognitively normal elderly subjects with hypertension. Stroke 2008; 39: 349-354. (Pubitemid 351619454)
42. Braak H, Braak E. Staging of Alzheimer-related cortical destruction. Int Psychogeriatr 1997; 9(Suppl 1): 257-261.
43. Jack Jr CR, Petersen RC, Xu Y, O'Brien PC, Smith GE, Ivnik RJ et al. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology 2000; 55: 484-489. (Pubitemid 30647242)
44. de Leeuw FE, Barkhof F, Scheltens P. White matter lesions and hippocampal atrophy in Alzheimer's disease. Neurology 2004; 62: 310-312. (Pubitemid 38167149)
45. Dufouil C, Chalmers J, Coskun O, Besancon V, Bousser MG, Guillon P et al. Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke: The PROGRESS (Perindopril Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy. Circulation 2005; 112: 1644-1650. (Pubitemid 41324527)
46. Tzourio C, Anderson C, Chapman N, Woodward M, Neal B, MacMahon S et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003; 163: 1069-1075. (Pubitemid 36548935)
47. O'Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): A case-control study. Lancet 2010; 376: 112-123.
48. Forette F, Seux ML, Staessen JA, Thijs L, Birkenhager WH, Babarskiene MR et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998; 352: 1347-1351. (Pubitemid 28510916)
49. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: 1887-1898. (Pubitemid 351620109)
50. Special Issue 'Basics of Alzheimer's Disease Prevention'. J Alzheimer's Dis 2010; 20 (guest editor: Jack de la Torre).
51. Special Issue 'Vascular Factors in Alzheimer's Disease'. Ann NY Acad Sci 2000; 903.
52. Kalaria R, Ince P. Vascular factors in Alzheimer's disease. Ann NY Acad Sci 2000; 903.
53. Qi JP, Wu H, Yang Y, Wang DD, Chen YX, Gu YH et al. Cerebral ischemia and Alzheimer's disease: The expression of amyloid-beta and apolipoprotein E in human hippocampus. J Alzheimers Dis 2007; 12: 335-341.
54. Nihashi T, Inao S, Kajita Y, Kawai T, Sugimoto T, Niwa M et al. Expression and distribution of beta amyloid precursor protein and beta amyloid peptide in reactive astrocytes after transient middle cerebral artery occlusion. Acta Neurochir (Wien) 2001; 143: 287-295. (Pubitemid 32268603)
55. Popa-Wagner A, Schroder E, Walker LC, Kessler C. Beta-amyloid precursor protein and ss-amyloid peptide immunoreactivity in the rat brain after middle cerebral artery occlusion: Effect of age. Stroke 1998; 29: 2196-2202. (Pubitemid 28443539)
56. Hall ED, Oostveen JA, Dunn E, Carter DB. Increased amyloid protein precursor and apolipoprotein E immunoreactivity in the selectively vulnerable hippocampus following transient forebrain ischemia in gerbils. Exp Neurol 1995; 135: 17-27.
57. Li L, Zhang X, Yang D, Luo G, Chen S, Le W. Hypoxia increases Abeta generation by altering beta- and gamma-cleavage of APP. Neurobiol Aging 2009; 30: 1091-1098.
58. Sun X, He G, Qing H, Zhou W, Dobie F, Cai F et al. Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression. Proc Natl Acad Sci USA 2006; 103: 18727-18732. (Pubitemid 44913478)
59. Wen Y, Onyewuchi O, Yang S, Liu R, Simpkins JW. Increased beta-secretase activity and expression in rats following transient cerebral ischemia. Brain Res 2004; 1009: 1-8. (Pubitemid 38553842)
60. Cullen K, Kocsi Z, Stone J. Microvascular pathology in the aging human brain: Evidence that senile plaques are sites of microhaemorrhages. Neurobiol Aging 2006; 27: 1786-1796. (Pubitemid 44572582)
61. Ogunshola OO, Antoniou X. Contribution of hypoxia to Alzheimer's disease: Is HIF-1alpha a mediator of neurodegeneration? Cell Mol Life Sci 2009; 66: 3555-3563.
62. Ray M, Ruan J, Zhang W. Variations in the transcriptome of Alzheimer's disease reveal molecular networks involved in cardiovascular diseases. Genome Biol 2008; 9: R148.
63. Myers RH, Schaefer EJ, Wilson PW, D'Agostino R, Ordovas JM, Espino A et al. Apolipoprotein E epsilon4 association with dementia in a population-based study: The Framingham study. Neurology 1996; 46: 673-677.
64. Wilson PW, Schaefer EJ, Larson MG, Ordovas JM. Apolipoprotein E alleles and risk of coronary disease. A meta-analysis. Arterioscler Thromb Vasc Biol 1996; 16: 1250-1255. (Pubitemid 26339712)
65. Licastro F, Chiapelli M, Caldarera CM, Caruso C, Lio D, Corder EH. Acute myocardial infarction and proinflammatory gene variants. Ann N Y Acad Sci 2007; 1119: 227-242. (Pubitemid 350191222)
66. Kalsheker NA. Alpha 1-antichymotrypsin. Int J Biochem Cell Biol 1996; 28: 961-964.
67. Ringelstein E, Koschorke S, Holling A. Computed Tomographic Patterns of Proven Embolic Brain Infarctions. Ann Neurol 1989; 26: 759-765. (Pubitemid 20011010)
68. Shi T, Iverson GM, Qi JC, Cockerill KA, Linnik MD, Konecny P et al. Beta 2-Glycoprotein I binds factor XI and inhibits its activation by thrombin and factor XIIa: Loss of inhibition by clipped beta 2-glycoprotein I. Proc Natl Acad Sci USA 2004; 101: 3939-3944. (Pubitemid 38381081)
69. Qiu C, Winblad B, Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol 2005; 4: 487-499. (Pubitemid 40982459)
70. Sharp SI, Aarsland D, Day S, Sonnesyn H, Ballard C. Hypertension is a potential risk factor for vascular dementia: Systematic review. Int J Geriatr Psychiatry 2011; 26: 661-669.
71. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K et al. Midlife vascular risk factors and Alzheimer's disease in later life: Longitudinal, population based study. BMJ 2001; 322: 1447-1451. (Pubitemid 32575406)
72. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K et al. Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med 2002; 137: 149-155. (Pubitemid 34827510)
73. Ninomiya T, Ohara T, Hirakawa Y, Yoshida D, Doi Y, Hata J et al. Midlife and late-life blood pressure and dementia in Japanese elderly: The hisayama study. Hypertension 2011; 58: 22-28.
74. Yamada M, Kasagi F, Sasaki H, Masunari N, Mimori Y, Suzuki G. Association between dementia and midlife risk factors: The Radiation Effects Research Foundation Adult Health Study. J Am Geriatr Soc 2003; 51: 410-414. (Pubitemid 36348905)
75. Power MC, Weuve J, Gagne JJ, McQueen MB, Viswanathan A, Blacker D. The Association Between Blood Pressure and Incident Alzheimer Disease: A Systematic Review and Meta-analysis. Epidemiology 2011; 22: 646-659.
76. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L et al. 15-year longitudinal study of blood pressure and dementia. Lancet 1996; 347: 1141-1145. (Pubitemid 126512042)
77. Anstey K, von Sanden C, Salim A, O'Kearney R. Smoking as a risk factor for dementia and cognitive decline: A meta-analysis of prospective studies. Am J Epidemiol 2007; 166: 367-378. (Pubitemid 47216800)
78. Jan Biessels G, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: A systematic review. Lancet Neurol 2006; 5: 64-74. (Pubitemid 41790697)
79. Anstey KJ, Cherbuin N, Budge M, Young J. Body mass index in midlife and late-life as a risk factor for dementia: A meta-analysis of prospective studies. Obes Rev 2011; 12: E426-e437.
80. Luchsinger J, Reitz C, Honig L, Tang M, Shea S, Mayeax R. Aggregation of vascular risk factors and risk of incident Alzheimer's disease. Neurology 2005; 65: 545-551. (Pubitemid 41170713)
81. Kivipelto M, Ngandu T, Laatikainen T, Winblad B, Soininen H, Tuomilehto J. Risk score for the prediction of dementia risk in 20 years among middle aged people: A longitudinal, population-based study. Lancet Neurol 2006; 5: 735-741. (Pubitemid 44205512)
82. Staessen JA, Thijs L, Bieniaszewski L, O'Brien ET, Palatini P, Davidson C et al. Ambulatory monitoring uncorrected for placebo overestimates long-term antihypertensive action. Systolic Hypertension in Europe (SYST-EUR) Trial Investigators. Hypertension 1996; 27(Pt 1): 414-420. (Pubitemid 26082082)
83. Forette F, Seux ML, Staessen JA, Thijs L, Babarskiene MR, Babeanu S et al. The prevention of dementia with antihypertensive treatment: New evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 2002; 162: 2046-2052. (Pubitemid 35168212)
84. Prince MJ, Bird AS, Blizard RA, Mann AH. Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults. BMJ 1996; 312: 801-805. (Pubitemid 26099297)
85. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991; 265: 3255-3264.
86. Di Bari M, Pahor M, Franse LV, Shorr RI,Wan JY, Ferrucci L et al. Dementia and disability outcomes in large hypertension trials: Lessons learned from the systolic hypertension in the elderly program (SHEP) trial. Am J Epidemiol 2001; 153: 72-78. (Pubitemid 32041899)
87. van Gijn J. The PROGRESS Trial: Preventing strokes by lowering blood pressure in patients with cerebral ischemia. Emerging therapies: Critique of an important advance. Stroke 2002; 33: 319-320. (Pubitemid 34052237)
88. Arnold JM, Yusuf S, Young J, Mathew J, Johnstone D, Avezum A et al. Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 2003; 107: 1284-1290. (Pubitemid 36314412)
89. Khachaturian ZS. When will dementia become a curable disease and Alzheimer's a forgotten word? Alzheimers Dement 2006; 2: 1. (Pubitemid 43264478)
90. Haag MD, Hofman A, Koudstaal PJ, Breteler MM, Stricker BH. Duration of antihypertensive drug use and risk of dementia: A prospective cohort study. Neurology 2009; 72: 1727-1734.
91. Yamada H, Chen YN, Aihara M, Araie M. Neuroprotective effect of calcium channel blocker against retinal ganglion cell damage under hypoxia. Brain Res 2006; 1071: 75-80. (Pubitemid 43255477)
92. Wildburger NC, Lin-Ye A, Baird MA, Lei D, Bao J. Neuroprotective effects of blockers for T-type calcium channels. Mol Neurodegener 2009; 4: 44.
93. Korenkov AI, Pahnke J, Frei K, Warzok R, Schroeder HW, Frick R et al. Treatment with nimodipine or mannitol reduces programmed cell death and infarct size following focal cerebral ischemia. Neurosurg Rev 2000; 23: 145-150.
94. Mossakowski MJ, Gadamski R. Effect of a calcium channel blocker on the development of ischemic neuron damage in sector CA1 of the horn of Ammon in Mongolian gerbils]. Neuropatol Pol 1987; 25: 439-450.
95. Amenta F, Tayebati SK, Tomassoni D. Spontaneously hypertensive rat neuroanatomy: Applications to pharmacological research. Ital J Anat Embryol 2010; 115: 13-17.
96. Sabbatini M, Mignini F, Venarucci D, Vega JA, Amenta F. Effect of nicardipine treatment on the expression of neurofilament 200 KDa immunoreactivity in the brain of spontaneously hypertensive rats. Clin Exp Hypertens 2001; 23: 127-141. (Pubitemid 32183263)
97. Bezprozvanny I, Mattson MP. Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease. Trends Neurosci 2008; 31: 454-463.
98. Khachaturian Z. The five-five, ten-ten plan for Alzheimer's disease. Neurobiol Aging 1992; 13: 197-198; discussion 199.
99. Mattson MP, Cheng B, Davis D, Bryant K, Lieberburg I, Rydel RE. beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci 1992; 12: 376-389.
100. Arispe N, Rojas E, Pollard HB. Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: Blockade by tromethamine and aluminum. Proc Natl Acad Sci USA 1993; 90: 567-571. (Pubitemid 23028904)
101. Demuro A, Mina E, Kayed R, Milton SC, Parker I, Glabe CG. Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J Biol Chem 2005; 280: 17294-17300. (Pubitemid 41389198)
102. Grotta JC, Picone CM, Dedman JR, Rhoades HM, Strong RA, Earls RM et al. Neuronal protection correlates with prevention of calcium-calmodulin binding in rats. Stroke 1990; 21(11 Suppl): III28-III31.
103. Randall RD, Thayer SA. Glutamate-induced calcium transient triggers delayed calcium overload and neurotoxicity in rat hippocampal neurons. J Neurosci 1992; 12: 1882-1895.
104. Wang J, Ho L, Chen L, Zhao Z, Zhao W, Qian X et al. Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J Clin Invest 2007; 117: 3393-3402. (Pubitemid 350096995)
105. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I et al. Amyloidbeta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008; 14: 837-842.
106. Ferrington L, Miners JS, Palmer LE, Bond SM, Povey JE, Kelly PA et al. Angiotensin IIinhibiting drugs have no effect on intraneuronal Abeta or oligomeric Abeta levels in a triple transgenic mouse model of Alzheimer's disease. Am J Transl Res 2011; 3: 197-208.
107. Hoffman LB, Schmeidler J, Lesser GT, Beeri MS, Purohit DP, Grossman HT et al. Less Alzheimer disease neuropathology in medicated hypertensive than nonhypertensive persons. Neurology 2009; 72: 1720-1726.
108. Cullen K, Stone J. Vascular relationships of heam-rich deposits in the aging cerebral cortex. J Cereb Blood Flow Metab 2005; 25: 1656-1667. (Pubitemid 41683176)
109. Scheff SW, Price DA. Synaptic pathology in Alzheimer's disease: A review of ultrastructural studies. Neurobiol Aging 2003; 24: 1029-1046. (Pubitemid 37487881)
110. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R et al. Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991; 30: 572-580.
111. Paris D, Town T, Mori T, Parker TA, Humphrey J, Mullan M. Soluble beta-amyloid peptides mediate vasoactivity via activation of a pro-inflammatory pathway. Neurobiol Aging 2000; 21: 183-197. (Pubitemid 30387077)